InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s
IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, is sharing details regarding its drug candidate TGR-63, which targets amyloid-beta plaque and has potential to improve Alzheimer's disease treatment in a significant manner. According to the announcement, preclinical trial data shows TGRr-63 reduces plaque in Alzheimer's. The company observed that “a key pathological marker of Alzheimer’s disease is the formation of abnormal clusters of protein fragments…